Castleman disease — UCD, HHV-8-associated MCD, iMCD (TAFRO/NOS/IPL), POEMS-associated MCD
Rare lymphoproliferative disorder family. Unicentric Castleman disease (UCD) involves a single lymph-node region and is often curable with surgical resection. Multicentric Castleman disease (MCD) involves multiple lymph-node regions with systemic inflammatory disease driven by cytokine storm, IL-6 dominant. MCD subtypes: HHV-8-associated MCD (KSHV-related; standard-of-care RITUXIMAB (Rituxan, Roche/Genentech) plus antiretrovirals in HIV-positive patients); HHV-8-negative idiopathic multicentric Castleman disease (iMCD), subdivided into iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly), iMCD-NOS, and iMCD-IPL; POEMS-associated MCD. Standard-of-care peptide/protein therapies: SILTUXIMAB (Sylvant, EUSA Pharma/Recordati) chimeric anti-IL-6 mAb FDA April 2014 for HHV-8-negative iMCD — first and only FDA-approved iMCD therapy; IV every 3 weeks. TOCILIZUMAB (Actemra, Roche/Chugai) anti-IL-6 receptor mAb approved in JAPAN for iMCD since 2005 — multi-jurisdictional reality preceding the US approval by nearly a decade; off-label in the US. iMCD is fatal without treatment in severe flares. Castleman Disease Collaborative Network (CDCN, castlemannetwork.org) is the international research and patient-advocacy consortium. Eighty-fifth deliberate non-elevation of community peptides.
What changes during this transition
Castleman disease is a family of rare lymphoproliferative disorders that splits sharply along two axes — unicentric versus multicentric, and (within multicentric) HHV-8-associated versus HHV-8-negative idiopathic versus POEMS-associated. Unicentric Castleman disease (UCD) involves a single lymph-node region: surgical resection of the involved nodal mass is often definitive, and the post-resection patient may carry no ongoing disease burden at all. Multicentric Castleman disease (MCD) is the opposite editorial situation — multiple lymph-node regions, systemic inflammatory disease driven by cytokine storm, and (in iMCD subtypes especially) a fatal trajectory in severe flares if untreated. The dominant cytokine in most MCD is IL-6, which is the load-bearing biology shaping the entire therapeutic landscape. HHV-8-associated MCD (KSHV-related) is the form most associated with HIV-positive patients; standard of care is RITUXIMAB (Rituxan, Roche/Genentech) anti-CD20 mAb together with antiretroviral therapy where HIV co-infection is present. HHV-8-negative MCD is idiopathic MCD (iMCD), and 2017 CDCN international consensus criteria subdivided iMCD into iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly — aggressive cytokine-storm phenotype, often multi-organ failure presentation), iMCD-NOS, and iMCD-IPL (idiopathic plasmacytic lymphadenopathy). POEMS-associated MCD overlaps the POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes) picture. SILTUXIMAB (Sylvant, EUSA Pharma/Recordati) is a chimeric anti-IL-6 monoclonal antibody FDA-approved April 2014 for HHV-8-negative iMCD on the strength of the only Phase 2 RCT ever conducted in the disease — both the first and (still) the only FDA-approved iMCD therapy; IV Q3wk. TOCILIZUMAB (Actemra, Roche/Chugai) is an anti-IL-6 receptor monoclonal antibody approved in JAPAN for iMCD since 2005 — nearly a decade before siltuximab's FDA approval, and the Japanese approval is real multi-jurisdictional clinical evidence per Rule 11; tocilizumab is used off-label for iMCD in the US. Refractory iMCD-TAFRO often requires corticosteroids plus cyclosporine, bortezomib, sirolimus, or thalidomide in trials. Severe iMCD flares are fatal without treatment. The Castleman Disease Collaborative Network (CDCN, castlemannetwork.org) is the international research consortium and patient-advocacy organization driving cross-jurisdictional collaboration across the US, UK, Europe, Japan, and China — it publishes consensus diagnostic and treatment criteria, runs the ACCELERATE registry, and is the load-bearing patient resource for newly diagnosed families. Many Castleman patients live for years on combinations of IL-6 blockade plus corticosteroids plus additional immunosuppression, with metabolic, bone-density, and infection-risk consequences. No peptide in the Juno library has a discovery-card-defensible Castleman case. The substrate entries exist for honest /ask answers when users probe specific compounds: BPC-157's pro-angiogenic VEGF/eNOS mechanism is mechanistically problematic in a cytokine-storm lymphoproliferative disease + SC injection in chronic immunosuppression; NMN general-aging frame in patients on long-term IL-6 blockade plus corticosteroids; GH-axis trio (CJC-1295 + ipamorelin + tesamorelin) interacts with IL-6 axis and corticosteroid burden with Rule 6 non-propagation sharpest for tesamorelin; semaglutide for corticosteroid-induced metabolic syndrome. Eighty-fifth deliberate non-elevation.
Important caveat
Castleman disease is managed by hematology/oncology specialists familiar with the disease — Castleman Disease Collaborative Network (CDCN, castlemannetwork.org) coordinates international consensus; 2017 CDCN international consensus diagnostic criteria for iMCD define the diagnostic conversation. **UCD**: single lymph-node region; **SURGICAL RESECTION OFTEN CURATIVE**. **MCD PHENOTYPE STRATIFICATION LOAD-BEARING**: HHV-8 status + clinical phenotype reshape treatment algorithm entirely. **HHV-8-ASSOCIATED MCD**: KSHV-related; HIV-positive population especially; **RITUXIMAB (Rituxan, Roche/Genentech) anti-CD20 mAb** standard + antiretroviral therapy where HIV co-infection present. **HHV-8-NEGATIVE iMCD**: per CDCN 2017 criteria — **iMCD-TAFRO** (thrombocytopenia + anasarca + fever + reticulin fibrosis + organomegaly — aggressive cytokine-storm, often multi-organ failure), **iMCD-NOS**, **iMCD-IPL**. **POEMS-ASSOCIATED MCD**: polyneuropathy + organomegaly + endocrinopathy + monoclonal gammopathy + skin changes; neurology + hematology co-management. **STANDARD-OF-CARE PEPTIDE/PROTEIN THERAPIES**: **SILTUXIMAB (SYLVANT, EUSA Pharma/Recordati) chimeric anti-IL-6 mAb FDA APRIL 2014** for HHV-8-negative iMCD — first and only FDA-approved iMCD therapy; only Phase 2 RCT in disease; IV Q3wk. **TOCILIZUMAB (ACTEMRA, Roche/Chugai) anti-IL-6R mAb approved JAPAN 2005 for iMCD** — multi-jurisdictional reality predating US siltuximab approval by nearly a decade; off-label in US; real cross-jurisdictional evidence per Rule 11. **iMCD-TAFRO REFRACTORY**: corticosteroids + cyclosporine + bortezomib + sirolimus + thalidomide in trials; severe flares may require ICU-level cytokine-storm management. **iMCD FATAL WITHOUT TREATMENT IN SEVERE FLARES**. **CHRONIC DISEASE + LONG-TERM CORTICOSTEROID BURDEN**: many MCD patients live years on IL-6 blockade + corticosteroids + additional immunosuppression. **INFECTION-RISK SURVEILLANCE on chronic IL-6 blockade + steroids**: vaccination status + tuberculosis screen before IL-6 blockade + hepatitis B reactivation surveillance + injection-site infection risk for any SC peptide injection. **METABOLIC + BONE CONSEQUENCES OF CHRONIC STEROIDS**: bone density + lipid panel + HbA1c + DEXA at established cadence; semaglutide may be coordinated for steroid-induced metabolic syndrome. **CDCN ACCELERATE REGISTRY**: international Castleman patient registry; trial-access pathway. **NO Juno library peptide is surfaced as a Castleman discovery card** — substrate entries only with editorially deliberate non-elevation (85th such entry). **BPC-157**: pro-angiogenic VEGF/eNOS mechanism in cytokine-storm lymphoproliferative disease + SC injection in chronic immunosuppression; no Castleman characterization. **NMN**: general-aging framing in patients on long-term IL-6 blockade + corticosteroid burden; no Castleman characterization. **GH-AXIS TRIO**: CJC-1295 + ipamorelin + tesamorelin uncharacterized; GH/IGF-1 interaction with IL-6 + chronic corticosteroid burden uncharacterized; **Rule 6 non-propagation SHARP for tesamorelin** (HIV-LD label does NOT extend to Castleman, including HHV-8-associated MCD where HIV co-infection may overlap). **SEMAGLUTIDE**: corticosteroid-induced metabolic syndrome in chronic Castleman is a real coordination question — semaglutide is standard-of-care obesity/T2D therapy with hematology coordination layer. **PREGNANCY**: iMCD pregnancies high-risk; siltuximab + tocilizumab pregnancy decisions reviewed with hematology + MFM; rituximab pregnancy decisions for HHV-8-associated MCD similar. WADA athletes: siltuximab + tocilizumab + rituximab require TUE; community GH secretagogues prohibited.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.